{
    "Clinical Trial ID": "NCT01009918",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I Lisinopril",
        "  Patients receive oral lisinopril once daily.",
        "  lisinopril: Given orally",
        "INTERVENTION 2: ",
        "  Arm II Coreg CR\u00ae",
        "  Patients receive oral Coreg CR\u00ae once daily.",
        "  Coreg CR\u00ae: Given orally"
    ],
    "Eligibility": [
        "INCLUSION CRITERIA",
        "  Males and Females  18 years old diagnosed with HER2 positive breast cancer",
        "  Scheduled to receive neoadjuvant or adjuvant trastuzumab (Herceptin\u00ae) therapy (anthracycline-containing regimens are permitted). Patients receiving Herceptin\u00ae with their chemotherapy are permitted for eligibility work-up. Taxanes are permitted. Trastuzumab (Herceptin\u00ae) therapy may be given with or after primary chemotherapy. Pertuzumab may be used in conjunction with trastuzumab.",
        "  Left Ventricular Ejection Fraction (LVEF)  50% by MUGA scan or echocardiogram",
        "  Adequate renal function for administration of trastuzumab-containing chemotherapy regimen.",
        "  Sitting systolic blood pressure of > 90 mm Hg",
        "  Pulse  60 beats/minute",
        "  Not pregnant or breastfeeding",
        "  Female patients of childbearing potential, who are sexually active, must have a negative pregnancy test before starting the study",
        "  Both men and women must be willing to use effective contraception during the study. Teratogenicity is documented for both active study agents",
        "  Able to swallow capsules",
        "EXCLUSION CRITERIA:",
        "  Patients with metastatic disease",
        "  Prior treatment with trastuzumab or anthracyclines prior to this chemotherapy regimen",
        "  Current treatment with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), such as losartan, \u03b2-blockers or digoxin",
        "  Known cardiac history: heart failure, myocardial infarction, radiation-induced cardiac dysfunction",
        "  Known allergy to either ACE inhibitors or \u03b2-blockers",
        "  History of bronchial asthma or related bronchospastic conditions",
        "  Hereditary or idiopathic angioedema",
        "  History of severe hypersensitivity reactions to drugs or other causes, i.e. bee stings",
        "  This protocol does not exclude patients who are participating on other investigational studies. Refer to the local IRB guidelines."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Trastuzumab-Induced Cardiotoxicity After 52 Weeks of Treatment",
        "  Reduction in incidence of trastuzumab-induced cardiotoxicity after 52 weeks of treatment as measured by preservation of Left Ventricular Ejection Fraction (LVEF). Number of Patients who experienced a cardiotoxicity.",
        "  Time frame: 2 years",
        "Results 1: ",
        "  Arm/Group Title: Arm I Lisinopril",
        "  Arm/Group Description: Patients receive oral lisinopril once daily.",
        "  lisinopril: Given orally",
        "  Overall Number of Participants Analyzed: 152",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  45  29.6%",
        "Results 2: ",
        "  Arm/Group Title: Arm II Coreg CR  ",
        "  Arm/Group Description: Patients receive oral Coreg CR   once daily.",
        "  Coreg CR  : Given orally",
        "  Overall Number of Participants Analyzed: 147",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  43  29.3%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 5/158 (3.16%)",
        "  Anemia 1/158 (0.63%)",
        "  Febrile Neutropenia 0/158 (0.00%)",
        "  Spleen Disorder 0/158 (0.00%)",
        "  Palpitations 0/158 (0.00%)",
        "  Chest pain - cardiac 0/158 (0.00%)",
        "  Pericardial Effusion 1/158 (0.63%)",
        "  Colitis 0/158 (0.00%)",
        "  Diarrhea 1/158 (0.63%)",
        "  Fatigue 0/158 (0.00%)",
        "  Skin Infection 0/158 (0.00%)",
        "  Neutrophil Count Decreased 0/158 (0.00%)",
        "Adverse Events 2:",
        "  Total: 4/156 (2.56%)",
        "  Anemia 0/156 (0.00%)",
        "  Febrile Neutropenia 1/156 (0.64%)",
        "  Spleen Disorder 0/156 (0.00%)",
        "  Palpitations 0/156 (0.00%)",
        "  Chest pain - cardiac 0/156 (0.00%)",
        "  Pericardial Effusion 0/156 (0.00%)",
        "  Colitis 1/156 (0.64%)",
        "  Diarrhea 0/156 (0.00%)",
        "  Fatigue 1/156 (0.64%)",
        "  Skin Infection 0/156 (0.00%)",
        "  Neutrophil Count Decreased 1/156 (0.64%)"
    ]
}